12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Albiglutide: Phase III data

The double-blind Phase III Harmony 5 trial in 657 Type II diabetics on a background of metformin and glimepiride showed that once-weekly subcutaneous 30 mg albiglutide met the primary endpoint of reducing HbA1c from baseline to week 52 vs. placebo (0.55% vs. a gain of 0.33%, p<0.0001). Per the trial's protocol, a stepwise statistical analysis was first conducted comparing albiglutide to placebo followed by non-inferiority testing vs. Actos pioglitazone. Albiglutide missed the endpoint of non-inferiority to Actos in reducing HbA1c...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >